News | March 29, 2022
USFDA approves EUA for second booster dose of Moderna
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.
Launched in the year 2018, MedEngage Scholarship Program is aimed at nurturing and nourishing medical talent in India
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
Clinical trials for minimally invasive therapy procedures using advanced imaging from Philips Lung Suite start with successful first cases
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
It also empowers domestic precision immunotherapy for tumours and promotes the high-quality development of China's biopharmaceutical industry
Arizona-based, leading medical devices company, Confluent Medical Technologies, will be establishing a pilot manufacturing facility in Hyderabad.
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Subscribe To Our Newsletter & Stay Updated
